Geerligs Harm, Quanz Sandra, Suurland Brenda, Spijkers Ine E M, Rodenberg Jeff, Davelaar Frans G, Jongsma Berend, Kumar Mahesh
Fort Dodge Animal Health Holland, Bio R&D department, Van Houtenlaan 36, 1381 CP Weesp, The Netherlands.
Vaccine. 2008 Oct 16;26(44):5595-600. doi: 10.1016/j.vaccine.2008.07.080. Epub 2008 Aug 14.
The Marek's disease virus (MDV) vaccine strains CVI 988 and herpes virus of turkeys (HVT) strain FC126, usually are grown in primary chicken embryo fibroblasts (CEF). We found that the strains could be grown also in the so-called JBJ-1 cell line to titres in the same range as when chicken embryo fibroblasts were used. The JBJ-1 cell line is a fibroblast-like continuous chicken cell line, which can be grown in flat bottom tissue culture flasks, roller bottles and on micro carriers. We investigated the efficacy of experimental CVI 988 vaccines grown in JBJ-1 cells and the efficacy of combinations of CVI 988 grown in JBJ-1 cells with HVT FC 126 also grown in JBJ-1 cells. The study was performed in accordance with European Pharmacopoeia monograph 0589 for live MDV disease vaccines. Groups of 1-day-old SPF chicks were vaccinated subcutaneously or intramuscularly, with 10(2.5) TCID50 per dose of CVI 988 alone or in combination with 500PFU per dose of HVT. As a control a group vaccinated with CVI 988 grown in CEF was included. One group was not vaccinated. Five days after vaccination all chickens were challenged with the very virulent MDV strain RB1B. After challenge the chickens were observed for a period of 70 days for signs of Marek's disease (MD). The protection induced by CVI 988 grown in JBJ-1 cells and the combination of CVI 988 and HVT-FC126 both grown in JBJ-1 cells, amply complied with the requirements of the European Pharmacopoeia which prescribes that the protection index should be at least 80%. The safety of the vaccines grown in JBJ-1 cells was tested in a field study in commercial layer chickens. No signs of MD were noticed during the study and no other signs attributable to the vaccine. It is concluded that the JBJ-1 cell line is a suitable substrate for the current vaccines against MD.
马立克氏病病毒（MDV）疫苗株CVI 988和火鸡疱疹病毒（HVT）株FC126通常在原代鸡胚成纤维细胞（CEF）中培养。我们发现这些毒株也能在所谓的JBJ - 1细胞系中生长，其滴度与使用鸡胚成纤维细胞时处于相同范围。JBJ - 1细胞系是一种成纤维细胞样的连续鸡细胞系，可在平底组织培养瓶、滚瓶以及微载体上生长。我们研究了在JBJ - 1细胞中培养的实验性CVI 988疫苗的效力，以及在JBJ - 1细胞中培养的CVI 988与同样在JBJ - 1细胞中培养的HVT FC 126的联合效力。该研究按照欧洲药典专论0589中关于MDV活疫苗的规定进行。将1日龄的SPF雏鸡分组，每剂量皮下或肌肉注射10(2.5) TCID50的CVI 988，单独使用或与每剂量500PFU的HVT联合使用。作为对照，纳入一组用在CEF中培养的CVI 988进行免疫的鸡。一组未进行免疫。免疫后5天，所有鸡用超强毒MDV株RB1B进行攻毒。攻毒后观察鸡群70天，观察马立克氏病（MD）症状。在JBJ - 1细胞中培养的CVI 988以及在JBJ - 1细胞中培养的CVI 988与HVT - FC126的联合疫苗所诱导的保护作用，充分符合欧洲药典规定的保护指数应至少为80%的要求。在商品蛋鸡的田间试验中测试了在JBJ - 1细胞中培养的疫苗的安全性。在研究期间未发现MD症状，也未发现其他可归因于疫苗的症状。得出结论，JBJ - 1细胞系是当前抗MD疫苗的合适底物。
